RESEARCH 20202021-10-13T14:56:39+11:00


The survival of children diagnosed with cancer has dramatically improved over the last 10 years. However, for children diagnosed with diffuse intrinsic pontine glioma (DIPG), a form of diffuse midline glioma (DMG), there are no effective pharmacological or immunological treatments available; median survival remains less than 10 months. In Australia, 101 children under the age of 15 die from cancer each year. Although incidence is seemingly rare, DMG including DIPG are responsible for 25% of these deaths.

Until Josie’s diagnosis, Matt’s research was focused on blood cancers, plus breast and colon cancers to a lesser degree. His research expertise saw him secure not one, but two, Early Career Fellowships via Cancer Institute NSW (2014-2016 and 2017-2019). Of such high quality was his work throughout, he was awarded the NSW Premier’s Award for Outstanding Research Fellow in 2019. In addition to the sound scientific research this award highlights, it is also given to those who actively engage with lay and scientific audiences, advocating scientific research and the development of community and industry linkage. Connecting with donors big and small Matt’s gracious receipt of a donation to RUN DIPG via Newcastle Permanent’s annual staff’s charitable donation scheme.

If you would like to organise a similar donation program through your employer or place of business, email hello@rundipg.org. 


We also aim to support the purchase and development of world-leading infrastructure to enhance and expedite research outcomes, and to assist in moving these treatment strategies into the clinic. A significant challenge faced by Australian families fighting DIPG/DMG is the lack of available clinical trials; the Cancer Signalling Research Group, with the support of RUN DIPG, are dedicated to identifying and initiating much needed clinical trial protocols and fast-tracking these all the way along the research-to-clinic pipeline.

Specific Funding Priorities in 2020

  • Ionising radiation equipment to test strategies to improve standard of care radiotherapy – $300,000
  • Robotics equipment to test improved drug targets – $250,000
  • Support of clinical trials $100,000/pa
  • Establishment of a three year RUN DIPG International Postdoctoral Research Fellowship – $200,000/pa
  • Scholarships to support the best and brightest junior researcher $105,000/pa
  • Project support to improve standard of care treatment $100,000

Donate now


PO Box 110
St Leonards NSW 1590


E | hello@rundipg.org

P | 0409 167 504


Go to Top